X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs BIOCON LTD - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES BIOCON LTD PIRAMAL ENTERPRISES/
BIOCON LTD
 
P/E (TTM) x 37.1 36.3 102.2% View Chart
P/BV x 3.7 4.8 76.6% View Chart
Dividend Yield % 0.7 1.5 42.9%  

Financials

 PIRAMAL ENTERPRISES   BIOCON LTD
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-16
BIOCON LTD
Mar-16
PIRAMAL ENTERPRISES/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,065496 214.8%   
Low Rs805397 203.0%   
Sales per share (Unadj.) Rs383.0174.3 219.8%  
Earnings per share (Unadj.) Rs55.144.8 123.0%  
Cash flow per share (Unadj.) Rs74.156.9 130.1%  
Dividends per share (Unadj.) Rs17.505.00 350.0%  
Dividend yield (eoy) %1.91.1 167.0%  
Book value per share (Unadj.) Rs719.9202.8 355.0%  
Shares outstanding (eoy) m172.56200.00 86.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.42.6 95.4%   
Avg P/E ratio x17.010.0 170.5%  
P/CF ratio (eoy) x12.67.8 161.1%  
Price / Book Value ratio x1.32.2 59.0%  
Dividend payout %31.811.2 284.7%   
Avg Mkt Cap Rs m161,34489,220 180.8%   
No. of employees `0003.84.4 85.7%   
Total wages/salary Rs m16,8986,363 265.6%   
Avg. sales/employee Rs Th17,472.67,894.5 221.3%   
Avg. wages/employee Rs Th4,466.91,441.2 309.9%   
Avg. net profit/employee Rs Th2,512.82,029.7 123.8%   
INCOME DATA
Net Sales Rs m66,09934,854 189.6%  
Other income Rs m2,425845 286.9%   
Total revenues Rs m68,52435,699 191.9%   
Gross profit Rs m18,7238,200 228.3%  
Depreciation Rs m3,2742,423 135.1%   
Interest Rs m9,388102 9,203.6%   
Profit before tax Rs m8,4856,520 130.1%   
Minority Interest Rs m3-744 -0.4%   
Prior Period Items Rs m1,5930-   
Extraordinary Inc (Exp) Rs m4575,754 7.9%   
Tax Rs m1,0322,569 40.2%   
Profit after tax Rs m9,5068,961 106.1%  
Gross profit margin %28.323.5 120.4%  
Effective tax rate %12.239.4 30.9%   
Net profit margin %14.425.7 55.9%  
BALANCE SHEET DATA
Current assets Rs m47,48839,932 118.9%   
Current liabilities Rs m104,36216,276 641.2%   
Net working cap to sales %-86.067.9 -126.8%  
Current ratio x0.52.5 18.5%  
Inventory Days Days4154 75.8%  
Debtors Days Days5186 59.4%  
Net fixed assets Rs m26,53239,101 67.9%   
Share capital Rs m3451,000 34.5%   
"Free" reserves Rs m114,02438,591 295.5%   
Net worth Rs m124,22140,556 306.3%   
Long term debt Rs m75,81220,724 365.8%   
Total assets Rs m308,35684,816 363.6%  
Interest coverage x1.964.9 2.9%   
Debt to equity ratio x0.60.5 119.4%  
Sales to assets ratio x0.20.4 52.2%   
Return on assets %6.110.7 57.3%  
Return on equity %7.722.1 34.6%  
Return on capital %10.019.0 52.5%  
Exports to sales %17.230.7 55.9%   
Imports to sales %6.620.4 32.4%   
Exports (fob) Rs m11,36210,717 106.0%   
Imports (cif) Rs m4,3647,105 61.4%   
Fx inflow Rs m14,43511,789 122.4%   
Fx outflow Rs m5,1838,393 61.7%   
Net fx Rs m9,2533,396 272.5%   
CASH FLOW
From Operations Rs m-67,7735,264 -1,287.5%  
From Investments Rs m-8,768-9,540 91.9%  
From Financial Activity Rs m76,19910,867 701.2%  
Net Cashflow Rs m-3426,591 -5.2%  

Share Holding

Indian Promoters % 52.9 40.4 130.9%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 4.0 8.4 47.6%  
FIIs % 26.6 10.7 248.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 19.9 82.9%  
Shareholders   93,274 109,995 84.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT LTD.  AUROBINDO PHARMA  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Negative Note; IT Sector Down 2.4%(11:30 am)

After opening the day on a negative note, share markets in India continued to witness losses. Sectoral indices are trading on a mixed note with stocks in the IT sector.

Related Views on News

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Biocon: High Other Income And Licensing Income Drive Growth (Quarterly Results Update - Detailed)

Nov 7, 2016

Biocon has announced its 2QFY17. The company has reported 19.8% YoY growth in net sales and profits of Rs 1.5 bn for the quarter. Here is our analysis of the results.

Biocon: Lower R&D Expenses Help Margin Expansion (Quarterly Results Update - Detailed)

Sep 19, 2016

Biocon has announced its 1QFY17. The company has reported 21.1% YoY growth in total income and 34.6% YoY increase in net profits. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Aug 18, 2017 12:51 PM

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES - AJANTA PHARMA COMPARISON

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS